Rogaratinib (BAY1163877) is being evaluated for safety and pharmacokinetics in Chinese patients with FGFR-positive refractory, locally advanced, or metastatic solid tumors. The focus on a specific patient population with high FGFR expression levels may position Bayer favorably in the targeted therapy market, particularly in oncology. Given the increasing emphasis on precision medicine, successful outcomes could enhance Bayer's portfolio in the competitive landscape of FGFR inhibitors, which includes other agents currently in development or on the market. The completion of this trial may also provide valuable data for future regulatory submissions and broaden the therapeutic indications for rogaratinib, potentially increasing its market share.